Santhera Pharmaceuticals Holding AG Logo

Santhera Pharmaceuticals Holding AG

Develops innovative medicines for rare neuromuscular and mitochondrial disorders.

SANN | SW

Overview

Corporate Details

ISIN(s):
CH1276028821
LEI:
54930035HAOFTTQH0U85
Country:
Switzerland
Address:
HOHENRAINSTRASSE 24, 4133 PRATTELN
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Santhera Pharmaceuticals Holding AG is a specialty pharmaceutical company focused on the development and commercialization of innovative medicines for patients with rare diseases. The company targets conditions with high unmet medical needs, primarily in the area of rare neuromuscular and mitochondrial disorders. Santhera's mission is to provide treatment options for diseases that severely impact the lives of affected children and adults and currently have limited or no available therapies. Its development efforts include advanced treatments such as gene therapy for conditions like LAMA2-deficient congenital muscular dystrophy (CMD).

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Santhera Pharmaceuticals Holding AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Santhera Pharmaceuticals Holding AG

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Santhera Pharmaceuticals Holding AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2022-01-11 N/A Non-Executive member Buy None 42,600.00 CHF
2022-01-10 N/A Executive member Buy None 14,420.00 CHF
2022-01-05 N/A Executive member Buy None 37,000.00 CHF

Peer Companies

bioMérieux Logo
Provides in vitro diagnostic solutions for clinical and industrial microbiology.
France
BIM
BiomX Inc. Logo
Develops phage therapies to target harmful bacteria in chronic diseases like cystic fibrosis.
United States of America
PHGE
BioNTech SE Logo
Pioneering mRNA immunotherapies and vaccines to combat cancer and infectious diseases.
United States of America
BNTX
BioPorto Logo
IVD company developing NGAL biomarkers for early acute kidney injury (AKI) risk assessment.
Denmark
BIOPOR
BioRestorative Therapies, Inc. Logo
A clinical-stage company developing stem cell therapies for pain, metabolic disorders, and aesthetics.
United States of America
BRTX
Biosergen AB Logo
Developing novel antifungal drugs for life-threatening infections in immunocompromised patients.
Sweden
BIOSGN
Bio Solution Co.,Ltd. Logo
Develops cell therapies for degenerative diseases and supplies bio-lab reagents for R&D.
South Korea
086820
Biosynex Logo
European manufacturer of rapid diagnostic tests for professionals and consumer self-tests.
France
ALBIO
BIO-TECHNE Corp Logo
Develops reagents and instruments for life sciences research and clinical diagnostic markets.
United States of America
TECH
biote Corp. Logo
Trains practitioners in hormone optimization using bioidentical pellets and nutraceuticals.
United States of America
BTMD

Talk to a Data Expert

Have a question? We'll get back to you promptly.